Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Samsung BioLogics : says no decision yet on producing Moderna's COVID-19 shot

05/13/2021 | 09:07pm EDT

SEOUL, May 14 (Reuters) - Samsung BioLogics Co Ltd said on Friday that no decision has been made yet on producing Moderna Inc's COVID-19 vaccine in South Korea after a local newspaper reported the two companies had agreed on a contract manufacturing deal.

The Chosun Ilbo reported that the biotech arm of Samsung Group has agreed to produce the Moderna vaccine in its plant in Songdo, part of which will be used for domestic vaccination, citing unnamed government and pharmaceutical industry sources.

Samsung BioLogics said in a filing to the stock exchange that it could confirm the report as no decision has been finalised. The decision will be made within a one-month time frame, a company official told Reuters by phone.

The statement follows a denial by Samsung and Pfizer Inc earlier this week of another media report that the two companies were working together to produce a COVID-19 vaccine developed by the U.S. firm and its German partner BioNTech .

The Moderna shot has yet to be approved in South Korea, but the second of three expert panels recommended approval for emergency use of the vaccine on Thursday, based on its safety and efficacy in Phase 3 late-stage trials in the United States. (Reporting by Sangmi Cha; Editing by Miyoung Kim and Leslie Adler)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -5.23% 207.41 Delayed Quote.98.54%
SAMSUNG BIOLOGICS CO.,LTD. 0.95% 853000 End-of-day quote.3.27%
All news about SAMSUNG BIOLOGICS CO.,LTD.
06/14MARKET CHATTER : Overseas, Institutional Investors Focus on Stocks that May Gain..
MT
06/09MARKET CHATTER : Samsung Biologics Signs $269 Million Drug Manufacturing Deal wi..
MT
06/08S.Korean stocks end lower, investors look to U.S. inflation data
RE
06/04MARKET CHATTER : Samsung Biologics, Israel's KAHR Medical Enter CDMO Deal for Ca..
MT
06/02Moderna plans mix of COVID-19 vaccine doses with new Lonza deal
RE
05/31SAMSUNG BIOLOGICSá : South Korea's Samsung Biologics to add mRNA vaccine product..
RE
05/24MODERNAá : and Samsung Biologics Announce Agreement for Fill-Finish Manufacturin..
AQ
05/24Samsung Biologics to Manufacture Moderna's COVID-19 Vaccine
MT
05/24Samsung BioLogics shares ease after jumping on vaccine deal
RE
05/22U.S. vaccine makers agree to produce more COVID-19 vaccines in South Korea
RE
More news
Financials
Sales 2021 1 434 B 1,28 B 1,28 B
Net income 2021 376 B 0,34 B 0,34 B
Net Debt 2021 180 B 0,16 B 0,16 B
P/E ratio 2021 150x
Yield 2021 -
Capitalization 56 439 B 50 495 M 50 456 M
EV / Sales 2021 39,5x
EV / Sales 2022 33,3x
Nbr of Employees 3 247
Free-Float 25,0%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts
Average target price
Last Close Price 853 000,00 
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers and Directors
NameTitle
John Chongbo Rim President, Chief Executive Officer & Director
Dong-Joong Kim Chief Financial Officer, Director & Senior VP
Tae-Han Kim Chairman
James J. Choi Managing Director & Head-Information Technology
Yong-Ho An Managing Director & Head-Process Technology
Sector and Competitors
1st jan.Capitalization (M$)
SAMSUNG BIOLOGICS CO.,LTD.3.27%50 495
CSL LIMITED4.75%103 884
WUXI BIOLOGICS (CAYMAN) INC.21.40%67 880
BIOGEN INC.61.99%59 716
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.30.69%48 336
ALEXION PHARMACEUTICALS, INC.16.26%40 148